Do Glucocorticoid Injections Increase the Risk of Knee Osteoarthritis Progression Over 5 Years?


Journal

Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795

Informations de publication

Date de publication:
08 2022
Historique:
revised: 25 01 2022
received: 08 07 2021
accepted: 09 03 2022
pubmed: 16 3 2022
medline: 30 7 2022
entrez: 15 3 2022
Statut: ppublish

Résumé

Recent findings have demonstrated that intraarticular (IA) glucocorticoid injections can be deleterious for knees with osteoarthritis (OA). This study was undertaken to assess, in a real-life setting, the risk of knee OA progression in patients who received IA glucocorticoid injections over a 5-year follow-up period. We used marginal structural modeling with inverse probability of treatment weighting to determine the causal association between IA glucocorticoid injections and the 5-year risk of disease progression in patients with symptomatic knee OA from the Knee and Hip Osteoarthritis Long-term Assessment cohort. OA progression was defined as an incident total knee replacement (TKR) and/or radiographic worsening (Kellgren/Lawrence [K/L] grade or joint space narrowing [JSN]). We also examined these outcomes in knees that received IA hyaluronan (IAHA) injections. Among the 564 patients with knee OA included in the study sample, 51 (9.0%) and 99 (17.5%) received IA glucocorticoid or IAHA injections, respectively, and 414 (63.1%) did not receive any injection during follow-up. Compared to untreated knees, those treated with IA glucocorticoid injections had a similar risk of incident TKR (hazard ratio [HR] 0.92 [95% confidence interval (95% CI) 0.20, 4.14]; P = 0.91) or K/L grade worsening (HR 1.33 [95% CI 0.64, 2.79]; P = 0.44). IAHA injections had no effect on the risk of TKR (HR 0.81 [95% CI 0.14, 4.63]; P = 0.81) or K/L grade worsening (HR 1.36 [95% CI 0.85, 2.17]; P = 0.20). Similar results were obtained for JSN, and when TKR and radiographic outcomes were combined. In this study, IA glucocorticoid injections for symptomatic knee OA did not significantly increase the 5-year risk of incident TKR or radiographic worsening. These findings should be interpreted cautiously and replicated in other cohorts.

Identifiants

pubmed: 35289131
doi: 10.1002/art.42118
doi:

Substances chimiques

Glucocorticoids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1343-1351

Informations de copyright

© 2022 American College of Rheumatology.

Références

Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet 2019;393:1745-59.
Jones IA, Togashi R, Wilson ML, Heckmann N, Vangsness CT Jr. Intra-articular treatment options for knee osteoarthritis [review]. Nat Rev Rheumatol 2019;15:77-90.
Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol 2020;72:220-33.
Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 2019;27:1578-89.
Bannuru RR, Natov NS, Obadan IE, Price LL, Schmid CH, McAlindon TE. Therapeutic trajectory of hyaluronic acid versus glucocorticoid in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum 2009;61:1704-11.
Wernecke C, Braun HJ, Dragoo JL. The effect of intra-articular glucocorticoid on articular cartilage: a systematic review. Orthop J Sports Med 2015;3:2325967115581163.
McAlindon TE, LaValley MP, Harvey WF, Price LL, Driban JB, Zhang M, et al. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA 2017;317:1967-75.
Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957;16:494-502.
Zeng C, Lane NE, Hunter DJ, Wei J, Choi HK, McAlindon TE, et al. Intra-articular glucocorticoid and the risk of knee osteoarthritis progression: results from the Osteoarthritis Initiative. Osteoarthritis Cartilage 2019;27:855-62.
Conaghan PG. Glucocorticoid and osteoarthritis progression: a confounded issue. Osteoarthritis Cartilage 2019;27:e5-6.
Singh JA, Yu S, Chen L, Cleveland JD. Rates of total joint replacement in the United States: future projections to 2020-2040 using the national inpatient sample. J Rheumatol 2019;46:1134-40.
Huynh C, Puyraimond-Zemmour D, Maillefert JF, Conaghan PG, Davis AM, Gunther KP, et al. Factors associated with the orthopaedic surgeon's decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1905 patients. Osteoarthritis Cartilage 2018;26:1311-8.
Altman R, Lim S, Steen RG, Dasa V. Hyaluronic acid injections are associated with delay of total knee replacement surgery in patients with knee osteoarthritis: evidence from a large U.S. health claims database. PLoS One 2015;10:e0145776.
Ong KL, Anderson AF, Niazi F, Fierlinger AL, Kurtz SM, Altman RD. Hyaluronic acid injections in medicare knee osteoarthritis patients are associated with longer time to knee arthroplasty. J Arthroplasty 2016;31:1667-73.
Delbarre A, Amor B, Bardoulat I, Tetafort A, Pelletier-Fleury N. Do intra-articular hyaluronic acid injections delay total knee replacement in patients with osteoarthritis-a Cox model analysis. PLoS One 2017;12:e0187227.
Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
Guillemin F, Rat AC, Roux CH, Fautrel B, Mazieres B, Chevalier X, et al. The KHOALA cohort of knee and hip osteoarthritis in France. Joint Bone Spine 2012;79:597-603.
Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-60.
Moodie EE, Stephens DA. Marginal structural models: unbiased estimation for longitudinal studies. Int J Public Health 2011;56:117-9.
Groll DL, To T, Bombardier C, Wright JG. The development of a comorbidity index with physical function as the outcome. J Clin Epidemiol 2005;58:595-602.
Eckstein F, Boudreau RM, Wang Z, Hannon MJ, Wirth W, Cotofana S, et al. Trajectory of cartilage loss within 4 years of knee replacement--a nested case-control study from the osteoarthritis initiative. Osteoarthritis Cartilage 2014;22:1542-9.
Kompel AJ, Roemer FW, Murakami AM, Diaz LE, Crema MD, Guermazi A. Intra-articular corticosteroid injections in the hip and knee: perhaps not as safe as we thought? Radiology 2019;293:656-63.
Arroll B, Goodyear-Smith F. Corticosteroid injections for osteoarthritis of the knee: meta-analysis. BMJ 2004;328:869.
Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med 2015;162:46-54.
Juni P, Hari R, Rutjes AW, Fischer R, Silletta MG, Reichenbach S, et al. Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst Rev 2015:CD005328.
Da Costa BR, Hari R, Juni P. Intra-articular glucocorticoid for osteoarthritis of the knee. JAMA 2016;316:2671-2.
Felson DT. Intra-articular glucocorticoid and knee osteoarthritis: interpreting different meta-analyses. JAMA 2016;316:2607-8.
Russell SJ, Sala R, Conaghan PG, Habib G, Vo Q, Manning R, et al. Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 study. Rheumatology (Oxford) 2018;57:2235-41.
Seror P, Pluvinage P, d'Andre FL, Benamou P, Attuil G. Frequency of sepsis after local corticosteroid injection (an inquiry on 1160000 injections in rheumatological private practice in France). Rheumatology (Oxford) 1999;38:1272-4.
Richardson SS, Schairer WW, Sculco TP, Sculco PK. Comparison of infection risk with corticosteroid or hyaluronic acid injection prior to total knee arthroplasty. J Bone Joint Surg Am 2019;101:112-8.
Uson J, Rodriguez-Garcia SC, Castellanos-Moreira R, O'Neill TW, Doherty M, Boesen M, et al. EULAR recommendations for intra-articular therapies. Ann Rheum Dis 2021;80:1299-305.
Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res Ther 2017;19:18.
MacFarlane LA, Yang H, Collins JE, Jarraya M, Guermazi A, Mandl LA, et al. Association of Changes in effusion-synovitis with progression of cartilage damage over eighteen months in patients with osteoarthritis and meniscal tear. Arthritis Rheumatol 2019;71:73-81.
Ashraf S, Mapp PI, Walsh DA. Contributions of angiogenesis to inflammation, joint damage, and pain in a rat model of osteoarthritis. Arthritis Rheum 2011;63:2700-10.
O'Neill TW, Parkes MJ, Maricar N, Marjanovic EJ, Hodgson R, Gait AD, et al. Synovial tissue volume: a treatment target in knee osteoarthritis (OA). Ann Rheum Dis 2016;75:84-90.
Conaghan PG, Hunter DJ, Cohen SB, Kraus VB, Berenbaum F, Lieberman JR, et al. Effects of a single intra-articular injection of a microsphere formulation of triamcinolone acetonide on knee osteoarthritis pain: a double-blinded, randomized, placebo-controlled, multinational study. J Bone Joint Surg Am 2018;100:666-77.
Raynauld JP, Buckland-Wright C, Ward R, Choquette D, Haraoui B, Martel-Pelletier J, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2003;48:370-7.
Spitzer AI, Richmond JC, Kraus VB, Gomoll A, Jones DG, Huffman KM, et al. Safety and efficacy of repeat administration of triamcinolone acetonide extended-release in osteoarthritis of the knee: a phase 3b, open-label study. Rheumatol Ther 2019;6:109-24.
Eckstein F, Guermazi A, Gold G, Duryea J, Le Graverand MP, Wirth W, et al. Imaging of cartilage and bone: promises and pitfalls in clinical trials of osteoarthritis. Osteoarthritis Cartilage 2014;22:1516-32.
Hitzl W, Wirth W, Maschek S, Cotofana S, Nevitt M, John MR, et al. Greater lateral femorotibial cartilage loss in osteoarthritis initiative participants with incident total knee arthroplasty: a prospective cohort study. Arthritis Care Res (Hoboken) 2015;67:1481-6.
Klocke R, Levasseur K, Kitas GD, Smith JP, Hirsch G. Cartilage turnover and intra-articular corticosteroid injections in knee osteoarthritis. Rheumatol Int 2018;38:455-9.
Henrotin Y, Bannuru R, Malaise M, Ea HK, Confavreux C, Bentin J, et al. Hyaluronan derivative HYMOVIS(R) increases cartilage volume and type ii collagen turnover in osteoarthritic knee: data from MOKHA study. BMC Musculoskelet Disord 2019;20:293.
Henrotin Y, Berenbaum F, Chevalier X, Marty M, Richette P, Rannou F. Reduction of the serum levels of a specific biomarker of cartilage degradation (Coll2-1) by hyaluronic acid (KARTILAGE(R) CROSS) compared to placebo in painful knee osteoarthritis patients: the EPIKART study, a pilot prospective comparative randomized double blind trial. BMC Musculoskelet Disord 2017;18:222.
Dasa V, Lim S, Heeckt P. Real-world evidence for safety and effectiveness of repeated courses of hyaluronic acid injections on the time to knee replacement surgery. Am J Orthop (Belle Mead NJ) 2018;47.
Shewale AR, Barnes CL, Fischbach LA, Ounpraseuth ST, Painter JT, Martin BC. Comparative effectiveness of intra-articular hyaluronic acid and corticosteroid injections on the time to surgical knee procedures. J Arthroplasty 2017;32:3591-7.
Hunter DJ, Altman RD, Cicuttini F, Crema MD, Duryea J, Eckstein F, et al. OARSI clinical trials recommendations: Knee imaging in clinical trials in osteoarthritis. Osteoarthritis Cartilage 2015;23:698-715.
Bucci J, Chen X, LaValley M, Nevitt M, Torner J, Lewis CE, et al. Progression of knee osteoarthritis with use of intraarticular glucocorticoids versus hyaluronic acid. Arthritis Rheumatol 2022;74:223-6.

Auteurs

Augustin Latourte (A)

Université de Paris, INSERM, UMR-S 1132 BIOSCAR, and Rheumatology Department, AP-HP, Lariboisière Hospital, Paris, France.

Anne-Christine Rat (AC)

Caen Normandie University, UMR-S 1075-Mobilités: Vieillissement, Pathologie, Santé COMETE, Caen, France, Rheumatology Department, CHU Caen, Caen, France, and Université de Lorraine, EA 4360, APEMAC, Nancy, France.

Abdou Omorou (A)

Université de Lorraine, EA 4360, APEMAC, and Inserm CIC 1433 Epidémiologie Clinique, CHRU Nancy, Université de Lorraine Vandoeuvre-lès-Nancy, Nancy, France.

Willy Ngueyon-Sime (W)

CHU Caen, Caen, France.

Florent Eymard (F)

Rheumatology Department, Henri Mondor Hospital, AP-HP, Créteil, France.

Jérémie Sellam (J)

Rheumatology Department, Sorbonne Université, AP-HP, Saint-Antoine Hospital, Inserm UMRS_938, FHU PaCeMM, Paris, France.

Christian Roux (C)

Rheumatology Department, CHU Pasteur 2, LAMHESS EA6309, UMR7277 iBV CNRS, Nice Sophia Antipolis University, France.

Hang-Korng Ea (HK)

Université de Paris, INSERM, UMR-S 1132 BIOSCAR, and Rheumatology Department, AP-HP, Lariboisière Hospital, Paris, France.

Martine Cohen-Solal (M)

Université de Paris, INSERM, UMR-S 1132 BIOSCAR, and Rheumatology Department, AP-HP, Lariboisière Hospital, Paris, France.

Thomas Bardin (T)

Université de Paris, INSERM, UMR-S 1132 BIOSCAR, and Rheumatology Department, AP-HP, Lariboisière Hospital, Paris, France.

Johann Beaudreuil (J)

Université de Paris, INSERM, UMR-S 1132 BIOSCAR, and Physical Medicine and Rehabilitation department, Lariboisière-Fernand Widal hospital, Paris, France.

Francis Guillemin (F)

Université de Lorraine, EA 4360, APEMAC, and Inserm CIC 1433 Epidémiologie Clinique, CHRU Nancy, Université de Lorraine Vandoeuvre-lès-Nancy, Nancy, France.

Pascal Richette (P)

Université de Paris, INSERM, UMR-S 1132 BIOSCAR, and Rheumatology Department, AP-HP, Lariboisière Hospital, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH